Tim Kong

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 19

Top Venues

McGill University Faculty of Science

McGill University Faculty of Science (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

McGill University Faculty of Science Jan 01 2018

Canada

Research Assistant :: Biochemistry

Education History

McGill University Faculty of Science May 01 2016 - Dec 31 2017

Canada

MSC :: Biochemistry

McGill University Faculty of Science Sep 01 2012 - Apr 30 2016

Canada

BSC :: Biochemistry

Publications

Xianbing Zhu, Zheng Fu, Kendall Dutchak, Azadeh Arabzadeh, Simon Milette, Jutta Steinberger, Geneviève Morin, Anie Monast, Virginie Pilon, Tim Kong, Bianca N Adams, Erika Prando Munhoz, Hannah J B Hosein, Tianxu Fang, Jing Su, Yibo Xue, Roni F Rayes, Veena Sangwan, Logan A Walsh, Guojun Chen, Abdel Razaq Ahmad A Alyasin, Jonathan D Spicer, Morag Park, David Dankort, Sidong Huang
Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer. Cancer research 84 (8) (2024)
Xianbing Zhu, Zheng Fu, Kendall Dutchak, Azadeh Arabzadeh, Simon Milette, Jutta Steinberger, Geneviève Morin, Anie Monast, Virginie Pilon, Tim Kong, Bianca N Adams, Erika Prando Munhoz, Hannah J B Hosein, Tianxu Fang, Jing Su, Yibo Xue, Roni F Rayes, Veena Sangwan, Logan A Walsh, Guojun Chen, Abdel Razaq Ahmad A Alyasin, Jonathan D Spicer, Morag Park, David Dankort, Sidong Huang
Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer. Cancer research 84 (8) (2024)
Angelo B A Laranjeira, Tim Kong, Steven C Snyder, Mary C Fulbright, Daniel A C Fisher, Daniel T Starczynowski, Stephen T Oh
In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood 143 (23) (2024)
Angelo Brunelli Albertoni Laranjeira, Tim Kong, Steven C Snyder, Mary C Fulbright, Daniel A C Fisher, Daniel T Starczynowski, Stephen T Oh
In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood (2024)
Angelo Brunelli Albertoni Laranjeira, Tim Kong, Steven C Snyder, Mary C Fulbright, Daniel A C Fisher, Daniel T Starczynowski, Stephen T Oh
In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood (2024)
Xianbing Zhu, Zheng Fu, Kendall Dutchak, Azadeh Arabzadeh, Simon Milette, Jutta Steinberger, Geneviève Morin, Anie Monast, Virginie Pilon, Tim Kong, Bianca N Adams, Erika Prando Munhoz, Hannah J B Hosein, Tianxu Fang, Jing Su, Yibo Xue, Roni F Rayes, Veena Sangwan, Logan A Walsh, Guojun Chen, Abdel Razaq Ahmad A Alyasin, Jonathan D Spicer, Morag Park, David Dankort, Sidong Huang
Co-targeting CDK4/6 and BRD4 promotes senescence and ferroptosis sensitivity in cancer. Cancer research (2024)
Angelo B A Laranjeira, Tim Kong, Steven C Snyder, Mary C Fulbright, Daniel A C Fisher, Daniel T Starczynowski, Stephen T Oh
In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood 143 (23) (2024)
Angelo B A Laranjeira, Tim Kong, Steven C Snyder, Mary C Fulbright, Daniel A C Fisher, Daniel T Starczynowski, Stephen T Oh
In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood 143 (23) (2024)
Angelo B A Laranjeira, Tim Kong, Steven C Snyder, Mary C Fulbright, Daniel A C Fisher, Daniel T Starczynowski, Stephen T Oh
In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood 143 (23) (2024)
Tim Kong, LaYow Yu, Angelo B A Laranjeira, Daniel A C Fisher, Fan He, Maggie J Cox, Stephen T Oh
Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms. American journal of hematology (2023)
Stephen T Oh, Ruben A Mesa, Claire N Harrison, Prithviraj Bose, Aaron T Gerds, Vikas K Gupta, Bart L Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah A Buckley, Shanthakumar Tyavanagimatt, Bryan G Harder, Karisse Roman-Torres, Jennifer Smith, Adam R Craig, John O Mascarenhas, Srdan Verstovsek
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood advances (2023)
Tim Kong, Angelo B A Laranjeira, Kangning Yang, Daniel A C Fisher, LaYow Yu, Laure Poittevin De La Frégonnière, Anthony Z Wang, Marianna B Ruzinova, Jared S Fowles, Mary C Fulbright, Maggie J Cox, Hamza Celik, Grant A Challen, Sidong Huang, Stephen T Oh
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nature cancer (2022)
Tim Kong, Angelo B A Laranjeira, Kangning Yang, Daniel A C Fisher, LaYow Yu, Laure Poittevin De La Frégonnière, Anthony Z Wang, Marianna B Ruzinova, Jared S Fowles, Mary C Fulbright, Maggie J Cox, Hamza Celik, Grant A Challen, Sidong Huang, Stephen T Oh
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nature cancer 4 (1) (2022)
Tim Kong, Angelo B A Laranjeira, Kangning Yang, Daniel A C Fisher, LaYow Yu, Laure Poittevin De La Frégonnière, Anthony Z Wang, Marianna B Ruzinova, Jared S Fowles, Mary C Fulbright, Maggie J Cox, Hamza Celik, Grant A Challen, Sidong Huang, Stephen T Oh
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nature cancer 4 (1) (2022)
Tim Kong, Angelo B A Laranjeira, Kangning Yang, Daniel A C Fisher, LaYow Yu, Laure Poittevin De La Frégonnière, Anthony Z Wang, Marianna B Ruzinova, Jared S Fowles, Mary C Fulbright, Maggie J Cox, Hamza Celik, Grant A Challen, Sidong Huang, Stephen T Oh
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nature cancer 4 (1) (2022)
Tim Kong, Angelo Brunelli Albertoni Laranjeira, Taylor Collins, Elisa S De Togni, Abigail J Wong, Mary C Fulbright, Marianna B Ruzinova, Hamza Celik, Grant A Challen, Daniel A C Fisher, Stephen T Oh
Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFkB pathway inhibition. Blood advances (2021)
Tim Kong, Ryuhjin Ahn, Kangning Yang, Xianbing Zhu, Zheng Fu, Geneviève Morin, Rachel Bramley, Nikki C Cliffe, Yibo Xue, Hellen Kuasne, Qinghao Li, Sungmi Jung, Anne V Gonzalez, Sophie Camilleri-Broet, Marie-Christine Guiot, Morag Park, Josie Ursini-Siegel, Sidong Huang
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers. Cancer research 80 (3) (2019)
Tim Kong, Yibo Xue, Regina Cencic, Xianbing Zhu, Anie Monast, Zheng Fu, Virginie Pilon, Veena Sangwan, Marie-Christine Guiot, William D Foulkes, John A Porco, Morag Park, Jerry Pelletier, Sidong Huang
eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. Molecular cancer therapeutics 18 (11) (2019)
Yibo Xue, Brian Meehan, Zheng Fu, Xue Qing D Wang, Pierre Olivier Fiset, Ralf Rieker, Cameron Levins, Tim Kong, Xianbing Zhu, Geneviève Morin, Lashanda Skerritt, Esther Herpel, Sriram Venneti, Daniel Martinez, Alexander R Judkins, Sungmi Jung, Sophie Camilleri-Broet, Anne V Gonzalez, Marie-Christine Guiot, William W Lockwood, Jonathan D Spicer, Abbas Agaimy, William A Pastor, Josée Dostie, Janusz Rak, William D Foulkes, Sidong Huang
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nature communications 10 (1) (2019)

Tim Kong.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Tim Kong